Conditions: Relapsed Breast Cancer Neoplasms, Breast
Keywords: ErbB1 ErbB2 GW572016 lapatinib Relapsed breast cancer dual tyrosine kinase inhibitor MBC EGFR Her-2/neu FISH amplification
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 9
Healthy volunteers: no

Brief summary:
This study will evaluate the safety and efficacy of lapatinib in combination with chemotherapy (capecitabine, docetaxel, nab-paclitaxel) in subjects with ErbB2-overexpressing breast cancer whose disease has progressed during or within 12 months after completion of trastuzumab-containing therapy in the neoadjuvant or adjuvant setting.

Detailed description:

Arms:
arm 1: Lapatinib is administered in combination with one of the following chemotherapies based on the discretion of the investigator : capecitabine, docetaxel or nab-paclitaxel.

Interventions: intervention 1: Lapatinib intervention 2: Capecitabine intervention 3: Docetaxel intervention 4: nab-Paclitaxel
Intervention descriptions: intervention 1: Small molecule tyrosine kinase inhibitor intervention 2: Chemotherapy intervention 3: Chemotherapy intervention 4: Chemotherapy

Protocol document: